Sei Investments Co. Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Sei Investments Co. grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 337,658 shares of the specialty pharmaceutical company’s stock after buying an additional 7,078 shares during the period. Sei Investments Co.’s holdings in Supernus Pharmaceuticals were worth $9,032,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Congress Wealth Management LLC DE increased its position in Supernus Pharmaceuticals by 37.8% during the 1st quarter. Congress Wealth Management LLC DE now owns 177,801 shares of the specialty pharmaceutical company’s stock valued at $6,065,000 after purchasing an additional 48,750 shares during the period. Russell Investments Group Ltd. increased its position in shares of Supernus Pharmaceuticals by 205.2% during the first quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock valued at $3,342,000 after buying an additional 65,880 shares during the period. Schroder Investment Management Group bought a new position in Supernus Pharmaceuticals in the fourth quarter worth about $15,685,000. Vanguard Group Inc. lifted its holdings in Supernus Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock worth $179,854,000 after buying an additional 142,551 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its position in Supernus Pharmaceuticals by 250.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 49,160 shares of the specialty pharmaceutical company’s stock valued at $1,781,000 after acquiring an additional 35,137 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $30.75 on Friday. The firm has a market capitalization of $1.69 billion, a P/E ratio of -106.03 and a beta of 0.88. Supernus Pharmaceuticals, Inc. has a one year low of $21.99 and a one year high of $35.44. The company’s 50-day simple moving average is $32.27 and its 200 day simple moving average is $30.42.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. During the same period in the prior year, the firm earned ($0.02) earnings per share. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several research reports. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Piper Sandler lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $41.00 to $36.00 in a research report on Wednesday, September 11th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.